Information for patients
Manufacturers have reported salbutamol shortages because of an increase in demand related to the current COVID-19 pandemic. Some patients will receive the Spanish-labelled salbutamol inhaler, which is being imported into Canada to help alleviate the shortage. Both Canadian and Spanish-labelled salbutamol inhalers are used in a comparable way. At this time, to manage and conserve supply, most patients should receive only one inhaler at a time when they go to refill their prescription.
Patients should contact their healthcare professional for more information.
Information for healthcare professionals
The Spanish-labelled salbutamol inhaler has the same active ingredient and concentration as salbutamol inhalers on the Canadian market, and is used in a comparable way.
Healthcare professionals are advised that the preparation for use instructions for the Spanish-labelled salbutamol inhaler may differ from those for the Canadian inhalers. Before using the Spanish-labelled salbutamol inhaler for the first time, or if it has not been used for several days or more, 1 spray should be released into the air away from the face to ensure it is working properly.
Pharmacists and other healthcare professionals should:
-
Inform patients that they are receiving a Spanish-labelled product.
-
Print this communication and make it available to patients and caregivers upon dispensing the Spanish-labelled product.
-
Review the preparation for use instructions for the Spanish-labelled inhaler with the patient when dispensing this product.
-
Remind patients to continue to follow the same routine cleaning instructions as with the Canadian product.
-
Supply only one inhaler at a time when patients go to refill their prescription, to manage and conserve supply.
-
Consult the product monographs for salbutamol inhalers on the Canadian market, available on Heath Canada’s Web site for salbutamol prescribing information.
While the label text of the imported salbutamol is in Spanish, a sticker will be added to the carton label including the distributor name: JAMP Pharma Corporation, phone number, website and unique bar code.
Please see Appendix A for images of Spanish-labelled salbutamol product.
Action taken by Health Canada
The Minister of Health signed the Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in relation to COVID-19. Drugs included on the
List of Drugs for Exceptional Importation and Sale referenced in the Interim Order are eligible for the exceptional importation and sale provisions provided for in the Interim Order. Health Canada has added Spanish-labelled Salbutamol Aldo-Union to this list, which permits its importation and sale.
Health Canada is communicating this important safety information to healthcare professionals and Canadians via the
Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication update will be further distributed through the MedEffect™ e-Notice email notification system, as well as through our website and social media channels, including LinkedIn and Twitter.